Companion Diagnostics Market Size & Forecast Report, 2034

Companion Diagnostics Market - By Product, By Disease Indication, By Technology, By End Use - Global Forecast, 2025 - 2034

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology and Scope

1.1&nbsp;&nbsp;&nbsp; Market scope and definitions

1.2&nbsp;&nbsp;&nbsp; Research design

1.2.1&nbsp;&nbsp;&nbsp; Research approach

1.2.2&nbsp;&nbsp;&nbsp; Data collection methods

1.3&nbsp;&nbsp;&nbsp; Data mining sources

1.3.1&nbsp;&nbsp;&nbsp; Global

1.3.2&nbsp;&nbsp;&nbsp; Regional/Country

1.4&nbsp;&nbsp;&nbsp; Base estimates and calculations

1.4.1&nbsp;&nbsp;&nbsp; Base year calculation

1.4.2&nbsp;&nbsp;&nbsp; Key trends for market estimation

1.5&nbsp;&nbsp;&nbsp; Primary research and validation

1.5.1&nbsp;&nbsp;&nbsp; Primary sources

1.6&nbsp;&nbsp;&nbsp; Forecast model

1.7&nbsp;&nbsp;&nbsp; Research assumptions and limitations

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Industry 3600 synopsis

2.2&nbsp;&nbsp;&nbsp; Key market trends

2.2.1&nbsp;&nbsp;&nbsp; Regional trends

2.2.2&nbsp;&nbsp;&nbsp; Products trends

2.2.3&nbsp;&nbsp;&nbsp; Disease indication trends

2.2.4&nbsp;&nbsp;&nbsp; Technology trends

2.2.5&nbsp;&nbsp;&nbsp; End Use trends

2.3&nbsp;&nbsp;&nbsp; CXO perspectives: Strategic imperatives

2.3.1&nbsp;&nbsp;&nbsp; Key decision points for industry executives

2.3.2&nbsp;&nbsp;&nbsp; Critical success factors for market players

2.4&nbsp;&nbsp;&nbsp; Future outlook and strategic recommendations

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp; Upward trend in disease prevalence among developing countries

3.2.1.2&nbsp;&nbsp;&nbsp; Surging number of pathology labs and services equipped with advanced diagnostic equipment in North America

3.2.1.3&nbsp;&nbsp;&nbsp; Technological advancements

3.2.1.4&nbsp;&nbsp;&nbsp; Increasing R&amp;D investment

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls and challenges

3.2.2.1&nbsp;&nbsp;&nbsp; Stringent regulatory framework

3.2.2.2&nbsp;&nbsp;&nbsp; High cost of product development

3.2.3&nbsp;&nbsp;&nbsp; Market opportunities

3.2.3.1&nbsp;&nbsp;&nbsp; Growing demand in remote and rural areas

3.2.3.2&nbsp;&nbsp;&nbsp; Integration with digital health platforms

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4&nbsp;&nbsp;&nbsp; Regulatory landscape

3.4.1&nbsp;&nbsp;&nbsp; North America

3.4.2&nbsp;&nbsp;&nbsp; Europe

3.4.3&nbsp;&nbsp;&nbsp; Asia Pacific

3.4.4&nbsp;&nbsp;&nbsp; Latin America

3.4.5&nbsp;&nbsp;&nbsp; Middle East and Africa

3.5&nbsp;&nbsp;&nbsp; Technology landscape

3.5.1&nbsp;&nbsp;&nbsp; Current technologies

3.5.2&nbsp;&nbsp;&nbsp; Emerging technologies

3.6&nbsp;&nbsp;&nbsp; Future market trends

3.7&nbsp;&nbsp;&nbsp; Patent analysis

3.8&nbsp;&nbsp;&nbsp; Gap analysis

3.9&nbsp;&nbsp;&nbsp; Porter&rsquo;s analysis

3.10&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2024

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company market share analysis

4.2.1&nbsp;&nbsp;&nbsp; North America

4.2.2&nbsp;&nbsp;&nbsp; Europe

4.2.3&nbsp;&nbsp;&nbsp; Asia Pacific

4.3&nbsp;&nbsp;&nbsp; Company matrix analysis

4.4&nbsp;&nbsp;&nbsp; Competitive analysis of major market players

4.5&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.6&nbsp;&nbsp;&nbsp; Key developments

4.6.1&nbsp;&nbsp;&nbsp; Mergers and acquisitions

4.6.2&nbsp;&nbsp;&nbsp; Partnerships and collaborations

4.6.3&nbsp;&nbsp;&nbsp; New product launches

4.6.4&nbsp;&nbsp;&nbsp; Expansion plans

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

5.1&nbsp;&nbsp;&nbsp; Key trends

5.2&nbsp;&nbsp;&nbsp; Instruments

5.3&nbsp;&nbsp;&nbsp; Consumables

5.4&nbsp;&nbsp;&nbsp; Services

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Disease Indication, 2021 - 2034 ($ Mn)

6.1&nbsp;&nbsp;&nbsp; Key trends

6.2&nbsp;&nbsp;&nbsp; Breast cancer

6.3&nbsp;&nbsp;&nbsp; Lung cancer

6.4&nbsp;&nbsp;&nbsp; Colorectal cancer

6.5&nbsp;&nbsp;&nbsp; Skin cancer

6.6&nbsp;&nbsp;&nbsp; Other diseases indications

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Technology, 2021 - 2034 ($ Mn)

7.1&nbsp;&nbsp;&nbsp; Key trends

7.2&nbsp;&nbsp;&nbsp; Immunohistochemistry

7.3&nbsp;&nbsp;&nbsp; In situ hybridization

7.4&nbsp;&nbsp;&nbsp; Polymerase chain reaction

7.5&nbsp;&nbsp;&nbsp; Genetic sequencing

7.6&nbsp;&nbsp;&nbsp; Other technologies

Chapter 8&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

8.1&nbsp;&nbsp;&nbsp; Key trends

8.2&nbsp;&nbsp;&nbsp; Hospitals

8.3&nbsp;&nbsp;&nbsp; Diagnostic laboratories

8.4&nbsp;&nbsp;&nbsp; Other End Use

Chapter 9&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

9.1&nbsp;&nbsp;&nbsp; Key trends

9.2&nbsp;&nbsp;&nbsp; North America

9.2.1&nbsp;&nbsp;&nbsp; U.S.

9.2.2&nbsp;&nbsp;&nbsp; Canada

9.3&nbsp;&nbsp;&nbsp; Europe

9.3.1&nbsp; &nbsp; Germany

9.3.2&nbsp; &nbsp; UK

9.3.3&nbsp; &nbsp; France

9.3.4&nbsp; &nbsp; Spain

9.3.5&nbsp; &nbsp; Italy

9.3.6&nbsp; &nbsp; Netherlands

9.4&nbsp;&nbsp;&nbsp; Asia Pacific

9.4.1&nbsp; &nbsp; China

9.4.2&nbsp; &nbsp;Japan

9.4.3&nbsp; &nbsp;India

9.4.4&nbsp; &nbsp;Australia

9.4.5&nbsp; &nbsp;South Korea

9.5&nbsp; &nbsp; Latin America

9.5.1&nbsp; &nbsp;Brazil

9.5.2&nbsp; &nbsp;Mexico

9.5.3&nbsp; &nbsp;Argentina

9.6&nbsp;&nbsp;&nbsp; Middle East and Africa

9.6.1&nbsp; &nbsp;South Africa

9.6.2&nbsp; Saudi Arabia

9.6.3&nbsp; &nbsp;UAE

Chapter 10&nbsp;&nbsp;&nbsp;Company Profiles

10.1&nbsp;&nbsp;&nbsp; Abbott Laboratories

10.2&nbsp;&nbsp;&nbsp; Amgen

10.3&nbsp;&nbsp;&nbsp; AstraZeneca

10.4&nbsp;&nbsp;&nbsp; Becton, Dickinson and Company

10.5&nbsp;&nbsp;&nbsp; Biogen

10.6&nbsp;&nbsp;&nbsp; Bristol Myers Squibb

10.7&nbsp;&nbsp;&nbsp; Eli Lilly and Company

10.8&nbsp;&nbsp;&nbsp; F. Hoffmann-La Roche

10.9&nbsp;&nbsp;&nbsp; Foundation Medicine

10.10&nbsp;&nbsp;&nbsp;Guardant Health

10.11&nbsp;&nbsp;&nbsp;Johnson &amp; Johnson

10.12&nbsp;&nbsp;&nbsp;Merck

10.13&nbsp;&nbsp;&nbsp;Myriad Genetics

10.14&nbsp;&nbsp;&nbsp;Pfizer

10.15&nbsp;&nbsp;&nbsp;Thermo Fisher Scientific 
&nbsp;

Companion Diagnostics Market

Inquiry Before Buying